To determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses listed in groups 8 and 9, as well as other rapidly emerging viruses that utilize the…
Ended Awarded Last action
- Contract number
- 75N93020F00001
- Awardee
-
Southern Research Institute UEI CDZJAJJHJMH5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $274,250
Award facts
- Contract value 74% obligated
-
- $274,250.00 Current, with exercised options
- $371,424.00 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Birmingham, AL 35205, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$61,750 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $336,000 |
About this award
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $371,424 firm fixed price delivery order to Southern Research Institute under the In Vitro Assessments of Antimicrobial Activity indefinite-delivery/indefinite-quantity master contract vehicle. The delivery order is to determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses listed in Groups 8 and 9, as well as other rapidly emerging viruses that utilize the same assay methodology. Place of performance is Birmingham, Alabama. The period of performance is from September 2020 through October 2022. No set aside designation was specified. The National Institute of Allergy and Infectious Diseases aims to advance the understanding, treatment and prevention of infectious diseases through collaborative research.
Description
To determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses listed in groups 8 and 9, as well as other rapidly emerging viruses that utilize the same assay methodology.
Quick answers
Who was awarded contract 75N93020F00001?
75N93020F00001 was awarded to Southern Research Institute by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 17, 2020.
How much is contract 75N93020F00001 worth?
The government has obligated $274,250 on 75N93020F00001. Its potential value, with all options, is $371,424.
Is contract 75N93020F00001 an order under another contract?
Yes. 75N93020F00001 is a delivery order under 75N93019D00015, an indefinite delivery contract, on In Vitro Assessments of Antimicrobial Activity (IVAAA).
Was contract 75N93020F00001 competed?
The extent of competition for 75N93020F00001 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award